Over half of patients had moderate or worse lung function at COPD diagnosis. 

START STRONG

WITH THE DUAL ACTION OF ANORO TO MAXIMIZE BRONCHODILATION VERSUS SPIRIVA HANDIHALER2-4

 

Defined as statistically significant improvements in lung function vs SPIRIVA HANDIHALER in two 24-week, randomized, blinded studies in patients with COPD. In a separate study versus SPIRIVA HANDIHALER, statistical significance cannot be inferred.3,4


*In a subset (n=366) of a managed-care population with a coded diagnosis of COPD severity based on GOLD stages 2 to 4
1

 

ANORO was studied in patients with moderate or worse COPD.

 

EXPLORE THE HEAD-TO-HEAD DATA

Get your patients started with ANORO

Co-pay card icon

Help eligible, commercially
insured patients save

Subject to eligibility. Restrictions apply.

 

SEE SAVINGS OFFER

ANORO-ELLIPTA-Inhaler-icon

Request samples of ANORO 

 

Help your COPD patients get started with ANORO.


REQUEST SAMPLES  

GSK For You logo

GSK offers financial assistance

 

We are commited to helping your patients access GSK medications.

 

SEE PATIENT RESOURCES

ANORO ELLIPTA inhaler
Download Coupon

Download and send a savings coupon offer for ANORO* to your eligible patients

 

     DOWNLOAD COUPON     
 
*Every download will have a unique number, so please download one per patient. Please see the coupon for complete rules and eligibility.
 

ANORO vs SPIRIVA: Efficacy

 

See how they compare in head-to-head efficacy trials


SEE THE EFFICACY DATA